These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3428841)

  • 1. Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
    Zannad F; Royer-Morrot MJ; Zakari I; Sadoul N; Royer RJ
    Fundam Clin Pharmacol; 1987; 1(3):219-24. PubMed ID: 3428841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous disopyramide in myocardial infarction: a haemodynamic study.
    Marrott PK; Nairn PL; Hill PD; Turner G; Sharman J
    N Z Med J; 1983 Jan; 96(723):4-7. PubMed ID: 6571755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
    Hillis WS; Tweddel A; Lorimer AR; Lawrie TD
    J Int Med Res; 1976; 4(1 Suppl):74-7. PubMed ID: 1026533
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide pharmacokinetics in patients with acute myocardial infarction.
    Pentikäinen PJ; Huikuri H; Jounela AJ; Wilen G
    Eur J Clin Pharmacol; 1985; 28(1):45-51. PubMed ID: 3987785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous disopyramide in acute myocardial infarction: a haemodynamic and pharmacokinetic study.
    Cameron J; Stafford W; Pritchard D; Norris R; Ravenscroft P
    J Cardiovasc Pharmacol; 1984; 6(1):126-31. PubMed ID: 6199595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1979; 205(5):417-23. PubMed ID: 443082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.
    Silke B; Frais MA; Verma SP; Reynolds GW; Hafizullah M; Kalra PA; Jackson NC; Taylor SH
    Br J Clin Pharmacol; 1986 Dec; 22(6):707-14. PubMed ID: 3105568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction.
    Weissberg PL; Matenga J; Hayler AM; Holt DW
    Ther Drug Monit; 1982; 4(3):277-80. PubMed ID: 7135457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of an anti-arrhythmic agent, disopyramide, in delayed action form ('Ritmoforine' Retard).
    Nauta IL; van de Calseyde JF
    Curr Med Res Opin; 1981; 7(4):215-26. PubMed ID: 7226872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.
    Iisalo E; Aaltonen L
    Br J Clin Pharmacol; 1984 Mar; 17(3):325-9. PubMed ID: 6712865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Delayed-action disopyramide in the treatment of hyperkinetic ventricular arrhythmia. A randomized clinical comparative study vs immediate-action disopyramide].
    Romanò M; Spinelli A; Cazzani E; Muzio L
    Clin Ter; 1991 Jul; 138(1):13-9. PubMed ID: 1834395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentration of disopyramide given as capsules and controlled release tablets.
    Arnman K; Graffner C; Rikner L; Ryden L; Voog L
    Eur J Clin Pharmacol; 1983; 24(2):199-203. PubMed ID: 6840167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous and oral disopyramide after myocardial infarction.
    Nicholls DP; Haybyrne T; Barnes PC
    Lancet; 1980 Nov; 2(8201):936-8. PubMed ID: 6107587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.